ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
52 announcements with these filters
Gland Pharma's shareholders approved the appointment of Xingli Wang as Non-Executive Non-Independent Director via postal ballot. The ordinary resolution passed with 97.07% of votes in favour.
Q2 FY27 revenue ₹18,336 Mn (+23% YoY), PAT ₹2,908 Mn (+58%), adj. EBITDA margin 27%. US CDMO and launches lead; India and RoW weak.
Gland Pharma reported Q2FY27 revenue of Rs. 18,336 Mn, up 23% YoY, and PAT of Rs. 2,908 Mn, up 58% YoY. The press release accompanies its quarterly financial results filing.
Gland Pharma Ltd reported revenue from operations of ₹1,834 Cr (+23.3% YoY) and net profit of ₹290.8 Cr (+58.3% YoY) for Q2 FY27.
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Gland Pharma Limited has filed the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Gland Pharma issued a postal ballot notice to seek shareholder approval for appointing Mr. Xingli Wang as Non-Executive Director. E-voting runs October 7 to November 5, 2026.
Gland Pharma Limited announced the resignation of director Wenjie Zhang and the appointment of Xingli Wang as a Non-Executive Non-Independent Director effective October 1, 2026.
Gland Pharma Limited's board approved a USD 21 million investment in its subsidiary, Gland USA, to acquire a 60% stake in Novelstar Pharma Inc. This acquisition facilitates business expansion in the USA.
Fosun Pharma Industrial Pte. Ltd. sold 98,97,000 shares of Gland Pharma Ltd via open market transactions. This reduced their stake from 51.76% to 45.76%.
Mirae Asset Mutual Fund sold 57,842 equity shares of Gland Pharma Limited via open market. This transaction represents a 0.04% stake reduction in the company.
Gland Pharma is acquiring Gland Pharma USA Inc. for ₹4.81 Crore to streamline its corporate structure by making it a direct wholly-owned subsidiary.
Gland Pharma approved acquiring its step-down subsidiary, Gland Pharma USA Inc., from another wholly-owned subsidiary to streamline corporate structure. The transaction costs USD 5,01,208.
Gland Pharma Limited granted 5,90,249 employee stock options to 124 employees under its ESOP 2025 scheme. These options are subject to specified vesting schedules and pricing.
Gland Pharma paid fines totaling ₹1.40 Lakh to NSE and BSE for a technical regulatory non-compliance breach. The company has since ensured compliance with shareholder approval.
Fosun Pharma Industrial Pte. Ltd., a promoter, sold 98,97,000 Gland Pharma shares in the open market. Its stake fell from 51.76% to 45.76%.
Gland Pharma announced that the USFDA completed a routine GMP inspection of its Visakhapatnam facility with zero Form 483 observations.
Gland Pharma Limited held its 48th Annual General Meeting on August 25, 2026. The company provided its proceedings and the Chairman's speech.
Gland Pharma reported strong Q1FY27 results with 20% revenue growth and 47% PAT growth. Management highlighted a major strategic CDMO contract and raised long-term CAGR outlook to 20% following recent business wins.
Gland Pharma Limited has appointed Mr. Deepak Sapra as the new Chief Executive Officer, effective from November 16, 2026.
Gland Pharma reports a strong start to FY27, driven by CDMO and B2B growth, though currency shifts significantly impacted the bottom line compared to the previous quarter.
Gland Pharma reported Q1FY27 revenue of ₹18,003 Mn (20% YoY) with PAT of ₹3,170 Mn (47% YoY). Growth was driven by CDMO product launches and B2B volume expansion in US and Europe.
Gland Pharma reported Q1 FY27 revenue of ₹1,800.3 Cr and PAT of ₹317 Cr, with 20% and 47% year-on-year growth respectively.
Gland Pharma Ltd reported revenue from operations of ₹1,800 Cr (+19.6% YoY) and net profit of ₹317 Cr (+47.1% YoY) for Q1 FY27.
Gland Pharma signed a strategic CDMO manufacturing agreement with a global pharmaceutical company. The partnership has an annualized revenue potential of approximately ₹855-950 Crore.
Gland Pharma signed a manufacturing and supply agreement with a global partner for sterile injectables. The partnership targets revenue from 2029 with 55 initial SKUs.
Gland Pharma signed a strategic manufacturing agreement with a global pharmaceutical company. The partnership has an annualized revenue potential of approximately ₹902.5 Crore.